| P50 | author | Kian Behbakht | Q56332429 |
| | R Katherine Alpaugh | Q88903151 |
| P2093 | author name string | Andrew K Godwin | |
| | Michael W Sill | |
| | Robert S Mannel | |
| | Kathleen M Darcy | |
| | Russell J Schilder | |
| | Kathy Q Cai | |
| | Stephen C Rubin | |
| | Steven Waggoner | |
| P2860 | cites work | Active-site inhibitors of mTOR target rapamycin-resistant outputs of mTORC1 and mTORC2 | Q21145847 |
| | Targeting tumorigenesis: development and use of mTOR inhibitors in cancer therapy | Q21198871 |
| | Quantitation of circulating tumor cells in blood samples from ovarian and prostate cancer patients using tumor-specific fluorescent ligands | Q24655544 |
| | Nonparametric Estimation from Incomplete Observations | Q25938997 |
| | Cancer statistics, 2008 | Q27860585 |
| | TOR, a central controller of cell growth | Q27933354 |
| | Phase II trial of bevacizumab in persistent or recurrent epithelial ovarian cancer or primary peritoneal cancer: a Gynecologic Oncology Group Study | Q28258045 |
| | Upstream and downstream of mTOR | Q28277365 |
| | Tumor cells circulate in the peripheral blood of all major carcinomas but not in healthy subjects or patients with nonmalignant diseases | Q28289395 |
| | Ras, PI(3)K and mTOR signalling controls tumour cell growth | Q29614734 |
| | Detection of mutations in EGFR in circulating lung-cancer cells | Q29615033 |
| | Circulating tumor cells, disease progression, and survival in metastatic breast cancer | Q29619276 |
| | Detection of circulating tumor cells from renal carcinoma patients: experiences of a two-center study. | Q30320163 |
| | Activity of sorafenib in recurrent ovarian cancer and primary peritoneal carcinomatosis: a gynecologic oncology group trial | Q30429122 |
| | Isolation and characterization of circulating tumor cells in patients with metastatic colorectal cancer | Q33255975 |
| | Lack of efficacy of 24-h infusional topotecan in platinum-refractory ovarian cancer: A Gynecologic Oncology Group trial | Q33330937 |
| | Phase II evaluation of 24-h continuous infusion topotecan in recurrent, potentially platinum-sensitive ovarian cancer: A Gynecologic Oncology Group study | Q33331940 |
| | Safety and pharmacokinetics of escalated doses of weekly intravenous infusion of CCI-779, a novel mTOR inhibitor, in patients with cancer | Q33360724 |
| | In vivo antitumor effects of the mTOR inhibitor CCI-779 against human multiple myeloma cells in a xenograft model | Q33362103 |
| | Treatment Options in Metastatic Renal Cell Carcinoma: Focus on mTOR Inhibitors | Q33985467 |
| | Altretamine (hexamethylmelamine) in platinum-resistant and platinum-refractory ovarian cancer: a Gynecologic Oncology Group phase II trial | Q34748619 |
| | Relationship of circulating tumor cells to tumor response, progression-free survival, and overall survival in patients with metastatic colorectal cancer | Q34790678 |
| | A Gynecologic Oncology Group phase II trial of the protein kinase C-beta inhibitor, enzastaurin and evaluation of markers with potential predictive and prognostic value in persistent or recurrent epithelial ovarian and primary peritoneal malignancie | Q35000494 |
| | Clinical development of mammalian target of rapamycin inhibitors | Q35038759 |
| | A phase II trial of CI-958 in recurrent platinum-sensitive ovarian carcinoma: a Gynecologic Oncology Group study. | Q54008322 |
| | A Network Algorithm for Performing Fisher's Exact Test in r × c Contingency Tables | Q56432190 |
| | Association of disease progression and poor overall survival with detection of circulating tumor cells in peripheral blood of patients with metastatic breast cancer | Q57756474 |
| | Circulating Tumor Cell Analysis in Patients with Progressive Castration-Resistant Prostate Cancer | Q63965940 |
| | Circulating Tumor Cell Number and Prognosis in Progressive Castration-Resistant Prostate Cancer | Q63965942 |
| | Phase II trial of CI-958 in recurrent platinum-refractory ovarian carcinoma. A Gynecologic Oncology Group Study | Q73265209 |
| | Tomudex (ZD1694, NSC 639186) in platinum-pretreated recurrent epithelial ovarian cancer: a phase II study by the Gynecologic Oncology Group | Q74628247 |
| | Monitoring expression of HER-2 on circulating epithelial cells in patients with advanced breast cancer | Q78347889 |
| | Evaluation of monoclonal humanized anti-HER2 antibody, trastuzumab, in patients with recurrent or refractory ovarian or primary peritoneal carcinoma with overexpression of HER2: a phase II trial of the Gynecologic Oncology Group | Q78785334 |
| | Comparison of two methods for enumerating circulating tumor cells in carcinoma patients | Q81162598 |
| | Circulating tumor cells in metastatic breast cancer: from prognostic stratification to modification of the staging system? | Q81952877 |
| | Antiangiogenic drugs in ovarian cancer | Q84386233 |
| | AKT1/PKBalpha kinase is frequently elevated in human cancers and its constitutive activation is required for oncogenic transformation in NIH3T3 cells | Q35747042 |
| | In vivo quantitation of rare circulating tumor cells by multiphoton intravital flow cytometry | Q35880206 |
| | Epithelial ovarian cancer: a review of current management | Q36252039 |
| | Mammalian target of rapamycin as a therapeutic target in leukemia | Q36321019 |
| | Systemic therapy for ovarian cancer: current status and new treatments | Q36485315 |
| | Integrating circulating tumor cell assays into the management of breast cancer | Q36883679 |
| | Clinical evaluation of M30 and M65 ELISA cell death assays as circulating biomarkers in a drug-sensitive tumor, testicular cancer | Q36897795 |
| | Molecular markers detecting circulating melanoma cells by reverse transcription polymerase chain reaction: methodological pitfalls and clinical relevance | Q37340909 |
| | mTOR is a promising therapeutic target both in cisplatin-sensitive and cisplatin-resistant clear cell carcinoma of the ovary | Q37346570 |
| | Detection of circulating tumor cells in bladder cancer patients | Q37356665 |
| | Current status on biologic therapies in the treatment of epithelial ovarian cancer | Q37453118 |
| | Targeting mTOR globally in cancer: thinking beyond rapamycin | Q37630203 |
| | Mammalian target of rapamycin: discovery of rapamycin reveals a signaling pathway important for normal and cancer cell growth | Q37645017 |
| | Involvement of mTORC1 and mTORC2 in regulation of glioblastoma multiforme growth and motility | Q39804812 |
| | Biochemical, cellular, and in vivo activity of novel ATP-competitive and selective inhibitors of the mammalian target of rapamycin | Q39827828 |
| | Regulation of D-cyclin translation inhibition in myeloma cells treated with mammalian target of rapamycin inhibitors: rationale for combined treatment with extracellular signal-regulated kinase inhibitors and rapamycin. | Q39896259 |
| | RAD001 inhibits human ovarian cancer cell proliferation, enhances cisplatin-induced apoptosis, and prolongs survival in an ovarian cancer model | Q40106656 |
| | Phase II study of oxaliplatin in platinum-resistant and refractory ovarian cancer: a gynecologic group study | Q40571931 |
| | AKT and mTOR phosphorylation is frequently detected in ovarian cancer and can be targeted to disrupt ovarian tumor cell growth | Q42463490 |
| | Akt/protein kinase B is constitutively active in non-small cell lung cancer cells and promotes cellular survival and resistance to chemotherapy and radiation | Q42504535 |
| | mTOR, a novel target in breast cancer: the effect of CCI-779, an mTOR inhibitor, in preclinical models of breast cancer | Q42660087 |
| | A phase II evaluation of bortezomib in the treatment of recurrent platinum-sensitive ovarian or primary peritoneal cancer: a Gynecologic Oncology Group study | Q43284690 |
| | Phase II trial of pyrazoloacridine in recurrent platinum-resistant ovarian cancer: a Gynecologic Oncology Group study | Q44528127 |
| | Randomized phase II study of multiple dose levels of CCI-779, a novel mammalian target of rapamycin kinase inhibitor, in patients with advanced refractory renal cell carcinoma | Q44551425 |
| | Circulating tumor cells in patients with castration-resistant prostate cancer baseline values and correlation with prognostic factors. | Q45977867 |
| | Prognostic significance of circulating tumor cells in patients with metastatic colorectal cancer | Q46090380 |
| | Phase II evaluation of imatinib mesylate in the treatment of recurrent or persistent epithelial ovarian or primary peritoneal carcinoma: a Gynecologic Oncology Group Study | Q46494607 |
| | Phase II study of gefitinib in patients with relapsed or persistent ovarian or primary peritoneal carcinoma and evaluation of epidermal growth factor receptor mutations and immunohistochemical expression: a Gynecologic Oncology Group Study | Q46630310 |
| | Evaluation of cisplatin and cyclosporin A in recurrent platinum-resistant ovarian cancer: a phase II study of the gynecologic oncology group | Q46756927 |
| | Phase II study of bevacizumab in patients with platinum-resistant ovarian cancer or peritoneal serous cancer | Q46892024 |
| | Frequent activation of AKT2 kinase in human pancreatic carcinomas | Q47251291 |
| | The Proof and Measurement of Association between Two Things | Q50368932 |
| | The treatment of ties in ranking problems | Q53055431 |
| | Phase II study of paclitaxel and valspodar (PSC 833) in refractory ovarian carcinoma: a gynecologic oncology group study. | Q53324757 |
| | A phase II trial of dolastatin-10 in recurrent platinum-sensitive ovarian carcinoma: a Gynecologic Oncology Group study. | Q53656621 |
| | [Rapamycin and CCI-779] | Q53805382 |
| | A phase I and pharmacokinetic study of temsirolimus (CCI-779) administered intravenously daily for 5 days every 2 weeks to patients with advanced cancer. | Q53984577 |
| P433 | issue | 1 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | gynecologic oncology | Q5625186 |
| | biomarker | Q864574 |
| | phase II clinical trial | Q42824440 |
| P304 | page(s) | 19-26 | |
| P577 | publication date | 2011-07-12 | |
| P1433 | published in | Gynecologic Oncology | Q5625182 |
| P1476 | title | Phase II trial of the mTOR inhibitor, temsirolimus and evaluation of circulating tumor cells and tumor biomarkers in persistent and recurrent epithelial ovarian and primary peritoneal malignancies: a Gynecologic Oncology Group study | |
| P478 | volume | 123 | |